In a lopsided 9-2 vote, an FDA expert panel on blood products has concluded that Nabi Biopharmaceuticals hepatitis B therapy should be approved as a therapy to prevent the recurrence of hepatitis B in liver transplant patients. The agency originally approved Nabi-HB seven years ago to prevent the disease after exposure. The panel came to a different conclusion than the agency's staff, which said that Nabi had not sufficiently demonstrated the efficacy of the drug in transplants. One analyst pegged the value of a new approval at about $3 million in new revenue next year.
- read the Sun-Sentinel's report on Nabi